The Subrenal Capsule Assay as a Predictor of Tumour Response in Gynaecological Oncology

  • R. E. Hunter
  • T. W. Griffin
  • S. D. Reich
  • J. M. Price
  • A. E. Bogden


Present cancer treatment requires selection of therapy for individual patients on the basis of clinical trials in large, heterogeneous populations of patients. Recent attention, however, has focused on the possibility of determining the susceptibility of an individual human malignancy to a therapeutic manoeuvre by means of prior laboratory testing of the tumour. The oestrogen receptor protein assay has demonstrated the clinical utility of this approach, by allowing selection of those patients more likely to respond to hormonal manipulation and exclusion of those patients unlikely to respond [1]. With regard to chemotherapeutic agents, attention has focused on the human tumour stem cell assay developed by Salmon and co-workers [2] and on the subrenal capsule assay developed by Bogden et al. [3].


Predictive Accuracy Endometrial Carcinoma Gynaecological Oncology Clinical Response Rate Human Tumor Xenograft 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McGuire WL, Horowitz KB, Zava DT et al. (1978) Hormones in breast cancer: Update 1978. Metabolism 27:487–501PubMedCrossRefGoogle Scholar
  2. 2.
    Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197:461–463PubMedCrossRefGoogle Scholar
  3. 3.
    Bogden AE, Cobb WR, Kelton DE, LePage DJ, Remington K, Cote TH (1978) A six-day subrenal capsule assay for drug screening using the normal immunocompetent mouse as host for human tumor xenografts (Abstr). Proc AACR and ASCO 19:105Google Scholar
  4. 4.
    Bogden AE, Haskell PM, LePage DJ, Kelton DE, Cobb WR, Esber HJ (1979) Human tumor xenografts implanted under the renal capsule of normal immunocompetent mice. Exp Cell Biol 47:281–293PubMedGoogle Scholar
  5. 5.
    Bogden AE, Cobb WR, LePage DJ et al. (1981) Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: 6-day subrenal capsule assay. Cancer 48:10–20PubMedCrossRefGoogle Scholar
  6. 6.
    Bogden AE, Cobb WR, LePage DL, Kelton DE (1981) Reproducibility of chemotherapy response profiles of human tumor explants in the 6-day subrenal capsule (SRC) assay (Abstr). Proc AACR and ASCO 22:224Google Scholar
  7. 7.
    Miller AB, Hoogstratten B, Staguet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRefGoogle Scholar
  8. 8.
    Griffin TW, Bogden AE, Reich SD et al. (to be published) Initial clinical trials of the subrenal capsule assay as a predictor of tumor response to chemotherapy. CancerGoogle Scholar
  9. 9.
    Hunter RE, Reich SD, Griffin TW, Bogden AE (1982) Responsiveness of gynecologic tumors to chemotherapeutic agents in the six-day subrenal capsule assay. Gynecol Oncol 14:298–306PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • R. E. Hunter
  • T. W. Griffin
  • S. D. Reich
  • J. M. Price
  • A. E. Bogden

There are no affiliations available

Personalised recommendations